Both restore declining hormones through mechanism-appropriate pathways rather than supraphysiological dosing
Belonging to a class of drugs called GLP-1 receptor agonists, Semaglutide was initially approved by the FDA for successfully managing diabetes
Once released, it performs several key jobs: Signals the brain to reduce hunger and slow eating Stimulates insulin release from the pancreas, lowering blood sugar Slows gastric emptying so you feel full for longer Reduces unnecessary cravings and snacking between meals In short, the more effectively your body releases GLP-1 after eating, the easier it becomes to maintain a balanced diet and healthy weight
Notably, similar concepts have emerged from studies on metformin, where interindividual variability in therapeutic response and gastrointestinal tolerability has been linked to differences in gut microbiota composition
The FDA, too, aims to revoke authorization for Citrus Red No